Back to Authors

Samii, Ali

A5080323879 | I201448701

Mayo Clinic

University of Washington

Citations 5

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease

Annals of Neurology | May 3, 2021 | Volume: 90 | Issue: 1 | Pages: 76-88

10.1002/ana.26094 | PMID 33938021

Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. Methods We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)

JAMA Neurology | November 16, 2015 | Volume: 73 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2015.2736 | PMID 26569098

PET studies of parkinsonism associated with mutation in the α-synuclein gene

Neurology | May 13, 2012 | Volume: 53 | Issue: 9 | Pages: 2097-2097

10.1212/wnl.53.9.2097 | PMID 10599788

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

Neurology | February 9, 2012 | Volume: 78 | Issue: 10 | Pages: 690-695

10.1212/wnl.0b013e318249f683 | PMID 22323755

Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease

Neurology | March 13, 2008 | Volume: 70 | Issue: 16_part_2 | Pages: 1456-1460

10.1212/01.wnl.0000304044.22253.03 | PMID 18337586